NEW YORK--(BUSINESS WIRE)--Investigators from Baylor College of Medicine (BCM) in collaboration with Immunai have published results from a clinical study in which Immunai’s technology helped identify BTG1 as a novel molecular target that can be used to enhance the potency of natural killer T (NKT)- and T cell-based cancer immunotherapy. The study was published today in Nature Medicine.
In the three years since Noam Solomon and Luis Voloch started Immunai, the company has quickly outgrown its digs.